Combination therapy, however, which includes a BRAF or MEK inhibitor, combined with glembatumumab vedotin (an antibody drug conjugate that targets GPNMB) inhibits GPNMB and effectively controls the growth of Melanoma. Here, BRAF is linked to melanoma.